Full Product Name
Anti-OPG Antibody
Product Gene Name
anti-OPG antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Purity/Purification
Affinity purified
Concentration
100ug/100ul (lot specific)
Storage Buffer
PBS, pH 7.4 with 0.02% Sodium Azide
Immunogen
Synthetic peptide conjugated to KLH
Preparation and Storage
This product is stable for several weeks at 4 degree C as an undiluted liquid. Dilute only prior to immediate use. For extended storage, aliquot contents and freeze at -20 degree C or below. Avoid cycles of freezing and thawing. Expiration date is one (1) year from date of receipt.
Other Notes
Small volumes of anti-OPG antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-OPG antibody
This gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined.
Applications Tested/Suitable for anti-OPG antibody
Peptide ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)
Application Notes for anti-OPG antibody
Peptide ELISA titer: 1:20,000-1:80,000
Western blot analysis: 1:200-1000
Immunohistochemistry: 1:50-200
Optimal dilutions/concentrations should be determined by the end user.
Western Blot (WB) of anti-OPG antibody
Immunohistochemistry (IHC) #2 of anti-OPG antibody
NCBI/Uniprot data below describe general gene information for OPG. It may not necessarily be applicable to this product.
NCBI Accession #
NP_002537.3
[Other Products]
NCBI GenBank Nucleotide #
NM_002546
[Other Products]
UniProt Secondary Accession #
O60236; Q53FX6; Q9UHP4; B2R9A8[Other Products]
UniProt Related Accession #
O00300[Other Products]
Molecular Weight
46,026 Da
NCBI Official Full Name
Homo sapiens tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B), mRNA
NCBI Official Synonym Full Names
tumor necrosis factor receptor superfamily, member 11b
NCBI Official Symbol
TNFRSF11B??[Similar Products]
NCBI Official Synonym Symbols
OPG; TR1; OCIF
??[Similar Products]
NCBI Protein Information
tumor necrosis factor receptor superfamily member 11B; osteoclastogenesis inhibitory factor; osteoprotegerin
UniProt Protein Name
Tumor necrosis factor receptor superfamily member 11B
UniProt Synonym Protein Names
Osteoclastogenesis inhibitory factor; Osteoprotegerin
UniProt Gene Name
TNFRSF11B??[Similar Products]
UniProt Entry Name
TR11B_HUMAN
NCBI Summary for OPG
The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]
UniProt Comments for OPG
TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.
Protein type: Secreted, signal peptide; Secreted; Inhibitor
Chromosomal Location of Human Ortholog: 8q24
Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region
Molecular Function: cytokine activity; receptor activity
Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; negative regulation of odontogenesis of dentine-containing teeth; apoptosis; response to estrogen stimulus; response to arsenic; negative regulation of bone resorption; signal transduction; skeletal development; response to nutrient
Disease: Paget Disease, Juvenile
Product References and Citations for anti-OPG antibody
(1) Rachner,T.D., Schoppet,M., Niebergall,U et,al 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.Biochem. Biophys. Res. Commun. 2008;368 (3):736-741.
Research Articles on OPG
1. This study suggests that OPG is secreted into the coronary circulation and is associated with concentric remodeling/hypertrophy of left ventricle.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.